In terms of the molecular phenotype, Bae et al.(2) explained that US‐detected cancers were more likely to have the luminal A phenotype than mammographically visible (MV) cancers, which are more likely to have the HER2 phenotype Dawood et al.(12) found that patients with HER2‐type and basal‐like cancers had worse survival outcomes relative to those with luminal A‐type cancers. Here, ERBB2 is linked to cancer.